JPMorgan Initiates Hims & Hers at Neutral Citing GLP-1 Pivot Risks

JPMorgan has initiated coverage of Hims & Hers Health, Inc. with a Neutral rating and a December 2027 price target of $32. The firm cites execution risks as the company shifts its business model away from compounded GLP-1 drugs toward branded, FDA-approved alternatives.

Although the transition introduces near-term uncertainty, analysts maintain a positive outlook regarding the firm’s operational trajectory. The company has demonstrated significant volume in its new partnership, fulfilling more than 125,000 shipments of Novo Nordisk’s Wegovy within the first six weeks of the collaboration.

"We believe the Novo partnership should more than offset compounded GLP-1 headwinds," said Bryan Smilek, analyst at JPMorgan, in a note to investors.

Financial Projections and Strategic Outlook

JPMorgan analysts project that Hims & Hers will generate $1.1 billion in GLP-1 related revenue by 2026, a 46% increase over current levels. This growth is expected to be anchored by the company's ability to leverage its existing infrastructure to distribute branded products at scale.

"We're positive on HIMS' vertical integration and leading brand scale and expansion across specialties & geos," Smilek added.

Regulatory and Legal Headwinds

Beyond the operational pivot, Hims & Hers is navigating legal and regulatory challenges that could impact its valuation. The company is facing an active Federal Trade Commission (FTC) complaint regarding its data privacy practices.

Additionally, the firm is the subject of a securities class action lawsuit. Investors are monitoring the case, with a lead-plaintiff deadline set for November 2, 2026. These legal hurdles add complexity to the company’s transition as it attempts to maintain its brand reputation while moving away from the compounding space toward a strictly regulated branded pharmaceutical model.

The Mechanics of the GLP-1 Pivot

Compounded medications are customized drugs created by pharmacists to meet the specific needs of individual patients, often used when FDA-approved versions are in short supply. By moving toward branded, FDA-approved drugs, Hims & Hers is trading the higher margins and flexibility of the compounding business for the regulatory stability and supply chain security of partnerships with large pharmaceutical manufacturers like Novo Nordisk. This transition is intended to mitigate risks associated with potential future FDA restrictions on compounded GLP-1 products.